Abbott (NYSE: ABT) has announced a new study to improve treatment for patients battling heart failure and atrial fibrillation (AFib). This will be the first of its kind study to offer a unique insight into an effective treatment for people suffering from both heart failures and AFib. This disease combination has significant challenges to physicians.
Treatment of AFib and heart failure combination challenging
Comorbidities exacerbate cardiovascular diseases in most patients, and additional problems required simultaneous management, which presents challenges when treating either condition. Unfortunately, clinical trials evaluating therapies that one can employ in tandem to manage cardiovascular comorbidities better tend to be rare. Only select companies offer treatments in a clinical care spectrum allowing for unique trial designs that can provide physicians with insights required to transform care decisions in the future.
Abbott’s new TAP-CHF trial aims to discover better management alternatives for patients with heart failure and AFib with preserved ejection fraction (HFpEF). HFpEF is a heart failure type where the heart fails to relax and fill with blood before pumping. When these conditions combine, they can be challenging for physicians to control since they put enhanced pressure on pulmonary arteries. Patients with these conditions are at risk of hospitalization, stroke, or death.
Abbott develops devices for heart failure treatment
The company is a leader in the development of medical devices for arrhythmias such as AFib and heart failure treatment. It is currently evaluating better treatment alternatives for this patient population to improve quality of life and better outcomes.
Abbot’s chief medical officer heart failure business, Philip Adamson, said that cardiovascular patients usually have at least one heart condition. Adamson noted that the company is better positioned to help the patients extend their life and improve quality of life by offering physicians enhanced therapy approaches that can address the heart disease’s entirety. He added that complex heart condition trials promise to provide enhanced insight and make significant health outcomes.